GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Rhea-AI Summary
GeoVax Labs, a biotechnology company focused on vaccine and cancer immunotherapy development, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York. David Dodd, the company's Chairman & CEO, will be part of a panel discussion on innovative therapies for solid tumors at 12:30 pm ET.
The company's senior management will also be available for one-on-one meetings with registered attendees. Interested parties can arrange meetings through their ROTH representative or by contacting GeoVax directly at info@geovax.com.
This participation highlights GeoVax's commitment to advancing its research and development in the field of cancer immunotherapies and human vaccines.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GOVX declined 3.64%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees.
| Panel Details: | |
| Title: | Innovative Therapies for Solid Tumors |
| Presenter: | David Dodd, Chairman & CEO |
| Date/Time: | October 9, 2024, 12:30 pm ET |
If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at info@geovax.com.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
When and where is GeoVax (GOVX) participating in the ROTH Healthcare Opportunities Conference?
What panel will GeoVax's CEO be speaking on at the ROTH conference?
How can investors arrange meetings with GeoVax (GOVX) management at the ROTH conference?
What is the main focus of GeoVax Labs (GOVX) as a biotechnology company?
